Time to go retweeted
🚨 Excited to announce the publication of @sarahjiesun's PhD work in @ImmunityCP!🚨Key finding: BCG vaccination reprograms the epigenetic landscape of human bone marrow progenitor cells, reshaping innate immune responses. Full study here in open access: authors.elsevier.com/c/1jcFF…
Elisabeth Bik @MicrobiomDigest, expert in scientific integrity: ‘We need to slow down scientific publishing'
english.elpais.com/science-t…
Time to go retweeted
SAMRC launches a documentary titled "Saving Lives: Sisonke”, it chronicles the historic vaccine study rollout in South Africa.
The Sisonke project, was an initiative led by Professors Glenda Gray, and Linda-Gail Bekker, CEO of @DTHF_SA
More on this: shorturl.at/gjmEL
Time to go retweeted
BCG vaccination reduces bovine tuberculosis transmission, improving prospects for elimination dlvr.it/T4tR9Z
Time to go retweeted
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits | PNAS pnas.org/doi/abs/10.1073/pna…
Time to go retweeted
This #WorldTBDay, the TB Vax ARM has outlined 3 wins for the field to achieve by 2026 in order to effectively advance TB vaccine R&D and ensure equitable and affordable access this decade.
📋 Read the wins & sign the petition to show your support: bit.ly/Wins4TBVax
ALT Graphic detailing the three wins to deliver new TB vaccines this decade. 1: Measurable increases in national and joint, multilateral funding and financing for TB vaccine R&D. 2: Explicit and transparent commitments and plans from developers and governments to ensure equitable access. 3: TB vaccines and TB R&D integrated into AMR and other relevant global health agendas. Endorse the TB Vax ARM wins at bit.ly/Wins4TBvax
Time to go retweeted
#PLOSPathogens: Multiple genetic loci influence vaccine-induced protection against Mycobacterium tuberculosis ... dx.plos.org/10.1371/journal.…
Time to go retweeted
Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis thelancet.com/journals/lanin…
Time to go retweeted
Just released: TB Treatment Pipeline Report 2023, detailing key updates in TB treatment R&D - including recently wrapped and in-progress treatment-shortening trials, and 22 new or repurposed drugs undergoing clinical trials. Read it here: treatmentactiongroup.org/res… #CROI2024
Time to go retweeted
At the #SAMRCMeeting the Unit Director Prof Rob Warren provided a glimpse into the innovative work happening at the Centre for #TBResearch during the @MRCza's gathering of intra and extramural research units. The Deputy Director Prof Loxton, is also representing @SuMBHG!
Our lab director is supporting the @RareGenomicsRSA group. Cupcakes for a good cause. Thank you @shahida_moosa and team for the great work you do. The LoxtonLab supports all the efforts! – at Cape Town, South Africa
Time to go retweeted
Cell state transition analysis identifies interventions that improve control of Mycobacterium tuberculosis infection by susceptible macrophages | Science Advances science.org/doi/10.1126/scia…
We are at @UCT_news IDM for the TB mini-symposium! Promises to be a good day with great science discussions.
@digby_warner @TomScriba @satvi_uct @MRCza @SUhealthsci @SuMBHG @Dannie_Kenny @Carly_Young @GoosenWynand @tbgenomics #tuberculosis – at Cape Town, South Africa
Time to go retweeted
Aging can influence the alveolar lining fluid and promote #Mycobacterium #tuberculosis growth and translocation: mucosalimmunology.org/articl…
Time to go retweeted
Proud to share our latest publication in Nature Communications nature.com/articles/s41467-0…
@ljiresearch @sudhasinipanda @bpeters @SetteLab
Time to go retweeted
I haven't read this yet, but it's intriguing: suggests that Ag85B (and other immunodominant++ Ags??) as the 'control' for vax is bad.
Mycobacterium tuberculosis Antigen 85B modifies BCG-induced anti-tuberculosis immunity and favors pathogen survival academic.oup.com/jleukbio/ar…
Time to go retweeted
TAG is proud to be part of IMPAACT4TB consortium that is supporting introduction of first-ever child-friendly rifapentine formulation for TB prevention. @TheLancetInfDis reports on consortium's work to bring this game-changing drug to affected communities: thelancet.com/journals/lanin…
Time to go retweeted
.@IAVI secured a $55 million grant from the @gatesfoundation to fund a Phase 2b trial for the TB vaccine candidate MTBVAC. The world needs improved vaccines to control TB, which requires diverse candidates to be tested.
iavi.org/news-resources/pres…